Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Although the BRAF inhibitors dabrafenib and vemurafenib have both proven successful against BRAF‐mutant melanoma, there seem to be differences in their mechanisms of action. Here, we show that dabrafenib is more effective at inhibiting the growth of NRAS‐mutant and KRAS‐mutant cancer cell lines than...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Oncol
Auteurs principaux: Phadke, Manali, Remsing Rix, Lily L., Smalley, Inna, Bryant, Annamarie T., Luo, Yunting, Lawrence, Harshani R., Schaible, Braydon J., Chen, Yian A., Rix, Uwe, Smalley, Keiran S. M.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5748485/
https://ncbi.nlm.nih.gov/pubmed/29112787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12152
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires